Hims & Hers has partnered with Eli Lilly to offer the pharmaceutical company's FDA-approved obesity treatments directly through its digital health platform. The agreement allows eligible patients to access Lilly's injectable Zepbound (tirzepatide) and oral Foundayo (orforglipron) through Hims & Hers, expanding access to branded GLP-1 medications without requiring patients to navigate separate prescription or purchasing platforms.
Under the partnership, Hims & Hers pharmacies will receive direct access to Lilly's medications at self-pay prices. Patients can complete a virtual consultation, receive a prescription when clinically appropriate and arrange home delivery through a single platform. Monthly self-pay pricing starts at $149 for Foundayo and $299 for Zepbound, providing patients with transparent pricing options for FDA-approved weight-loss treatments.
The integration builds on Hims & Hers' existing weight management services, which include ongoing clinical support, nutrition guidance, regular check-ins and access to a patient community. By combining medication access with virtual care and behavioral support, the company aims to provide a more comprehensive weight management experience while simplifying the treatment journey.
The agreement follows a similar partnership with Novo Nordisk, which began offering its branded Wegovy and Ozempic medications through Hims & Hers earlier this year. These collaborations reflect a broader shift in the company's obesity strategy away from compounded GLP-1 products and toward FDA-approved branded medications. Hims & Hers has also committed not to offer compounded copies of Lilly's GLP-1 treatments, while both companies emphasize that prescribing decisions will remain under the independent judgment of healthcare professionals.
The transition comes amid financial challenges for Hims & Hers. The company reported a $92 million loss in the first quarter and an $86 million loss in the second quarter, partly reflecting restructuring costs and expenses associated with exiting its compounded GLP-1 business. Although branded medications typically generate lower margins, the partnerships with Lilly and Novo Nordisk could help strengthen the company's position in the expanding obesity treatment market.
Click here to read the original news story.
